

BIOMARIN PHARMACEUTICAL INC
Form 8-K
December 23, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 17, 2013

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

000-26727
(Commission
File Number)

68-0397820
(IRS Employer
Identification No.)

770 Lindero Street, San Rafael, California
(Address of principal executive offices)

94901
(Zip Code)

Registrant's telephone number, including area code: (415) 506-6700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Contract of Purchase and Sale

On December 17, 2013, BioMarin Pharmaceutical Inc. (the *Company*), through its wholly-owned subsidiary, California Corporate Center Acquisition, LLC, a Delaware limited liability company (the *Purchaser Affiliate*), entered into a Contract of Purchase and Sale and Joint Escrow Instructions (the *Agreement*) to purchase that certain office complex and vacant land commonly known as the San Rafael Corporate Center, located in the City of San Rafael, County of Marin, California (the *SRCC*) from SR Corporate Center Phase One, LLC, and SR Corporate Center Phase Two, LLC (the *Phase Two Seller*), each a Delaware limited liability company (collectively, the *Sellers*). The *Company* currently leases approximately 40% of the complex, which the *Company* uses as its global headquarters.

Subject to the adjustments and prorations provided in the *Agreement*, the purchase price of the *SRCC* will be \$116,500,000. The *Company* has deposited \$10,000,000 into escrow in connection with the pending transaction. The deposit may be retained by the *Sellers* if applicable closing conditions are satisfied and the *Company* fails to close the transaction. The *Agreement* contains customary representations and warranties, covenants, closing conditions and termination provisions. The *Agreement* contemplates a closing date of January 22, 2014, but the *Company* and *Sellers* may agree to accelerate the closing to an earlier date and there is no guarantee that the *Company* will close the transaction as scheduled or at all.

As noted above, the *Company* currently leases certain premises at the *SRCC* pursuant to (i) that certain Lease (770 Lindaro Street) dated December 31, 2011 by and between the *Phase Two Seller* and the *Company* and (ii) that certain Lease (790 Lindaro Street) dated December 31, 2011 by and between the *Phase Two Seller* and the *Company*, each as amended to date (collectively, the *Affiliate Leases*). Other than with respect to the *Agreement* and the *Affiliate Leases*, there is no material relationship among the *Company* or any of its affiliates and the *Sellers*.

The foregoing descriptions of the *Agreement* are qualified in their entirety by reference to the full text of the *Agreement*, a copy of which will be filed as an exhibit to the *Company*'s Annual Report on Form 10-K for the year ended December 31, 2013.

Cautionary Statement Regarding Forward-Looking Statements

This Form 8-K contains forward-looking statements relating to, among other things, our purchase of our corporate headquarters and the expected timing for closing this acquisition. Our actual results could differ materially from those predicted or implied. Factors that could cause or contribute to such differences include, but are not limited to, the ability of the *Company* and the *Sellers* to satisfy applicable closing conditions under the *Agreement*. Undue reliance should not be placed on the forward-looking statements in this Form 8-K, which are based on information available to us on the date hereof. We assume no obligation to update such statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: December 23, 2013

By: /s/ G. Eric Davis
G. Eric Davis

Senior Vice President, General Counsel